Weekly RSV Vaccination Dashboard

About

The Weekly RSV Vaccination Dashboard is designed to share preliminary weekly in-season RSV vaccination information, including vaccination coverage estimates and intent for vaccination, using a variety of data sources including surveys, healthcare claims databases, electronic medical records, and immunization information systems (IISs). The Dashboard will be updated weekly as new data become available. These estimates might differ from estimates that could be published after the end of each season using different analytic methods or based on data sources not available during the season. Please email to share any feedback (VaxView@cdc.gov).
Weekly RSV Vaccination Dashboard

Data Summary

Data Updates‎

Data updates are scheduled each Wednesday during 11 AM – 1 PM ET. Data, visuals, and/or features may be changing and may not match their final state during this time.

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 75 years and older and 60─74 years with high-risk conditions for RSV are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Data and charts are available here.

As of October 5, 2024, among adults ≥75 years:

  • An estimated 36.9% (95% Confidence Interval: 32.2%-41.5%) reported having ever received an RSV vaccine.
    • An additional 13.9% (10.2%-17.5%) reported they definitely will get a vaccine,
  • Vaccination coverage varied by poverty status, health insurance status, urbanicity, race and ethnicity, disability status, and presence of a chronic medical condition.
  • Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are available.

As of October 5, 2024, among adults 60─74 years with a high-risk condition for RSV:

  • An estimated 29.0% (24.4%-33.5%) reported having ever received an RSV vaccine.
    • An additional 10.0% (5.6%-14.5%) reported they definitely will get a vaccine.
  • Vaccination coverage varied by sex, disability status, health insurance status, poverty status, and race and ethnicity.
  • Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are available.

Adult RSV Vaccinations Administered

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for adults 18 years and older, based on healthcare claims data. Data and charts are available here.

  • During August 12, 2023, through September 21, 2024, among adults ≥75 years:
    • An estimated 4.81 million doses of the RSV vaccine were administered in retail pharmacies. Of these, ~307,594 doses were administered since August 4, 2024.
    • An estimated ~94,900 doses of the RSV vaccine were administered in physicians’ medical offices. Of these, ~4,600 doses were administered since August 4, 2024.

Pregnant Persons RSV Coverage

Estimates of RSV vaccination coverage for pregnant persons 18─49 years are calculated using data from CDC's Vaccine Safety Datalink (VSD). VSD data includes electronic health records data from ten integrated health systems. Data and charts are available here.

  • As of October 5, 2024, among persons who were pregnant and at least 32 weeks gestation since September 1, 2024, overall coverage with the RSV vaccine was 26.1%.
  • Vaccination coverage was highest among non-Hispanic Asian (36.9%) pregnant persons and lowest among non-Hispanic Black (17.0%) pregnant persons.

Monthly Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females age 18─49 years with infants <8 months during the RSV season (born since April 1, 2024) are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report. Data and charts are available here.

  • As of September 2024, among females with an infant born since April 1, 52.7% reported that they would definitely get nirsevimab for their infant.

Data & Charts

Data & Charts‎

View available vaccination data using interactive maps, graphs, charts, and tables.

Archived 2023-24 Season Data & Charts

Other VaxView Vaccination Coverage Websites

The VaxView websites provide vaccination coverage data for all ages. Monitoring coverage for recommended vaccinations across the country helps CDC assess how well local areas, states, and the nation are protected from vaccine-preventable diseases.

Find additional vaccination coverage data on the VaxView Vaccination Coverage main page.

Prevent RSV

Adults 60 years and older and pregnant persons can protect themselves from RSV.

Learn more about RSV.

Print
Content Source:
National Center for Immunization and Respiratory Diseases